Afrezza denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for afrezza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Imposes Quantity Limits on Afrezza

Humana applies quantity limits to Afrezza (inhaled insulin) as a standard formulary utilization-management tool. These limits cap the number of units, cartridges, or packages the plan will cover per dispensing period. Denials occur when the prescribed quantity exceeds the plan's limit — often because the patient's clinical needs require a higher dose regimen than the default limit accommodates, or because the cartridge configuration needed for proper dosing does not align with the quantity formula.

## Why This Denial Is Appealable

Quantity-limit denials are not clinical determinations about whether Afrezza is appropriate — they are administrative caps. When a patient's individualized clinical need requires a quantity above the plan's limit, that difference is appeallable as a medical-necessity exception. Under ACA Section 2719 you have the right to internal appeal and independent external review by a federally accredited IRO. ERISA Section 503 applies to self-funded plans. The external-review window is typically around four months from the final internal denial; expedited review is available when delay would seriously jeopardize health.

## What Makes a Quantity-Limit Exception Succeed

1. Understand exactly what Humana's limit is. The denial notice or Humana's formulary documentation will state the approved quantity. Request the specific limit in writing so the appeal addresses the precise gap between what is allowed and what is prescribed.

2. Get the prescriber to document the clinical basis for the prescribed quantity. The prescriber's letter should explain why the prescribed regimen — and no lower quantity — is necessary for this patient. This should be grounded in the patient's documented response to insulin, glucose monitoring data, frequency of meals, and any other individualized clinical factors. Vague statements that more medication is needed are insufficient; the letter must tie the quantity to clinical evidence.

3. Reference the FDA-approved prescribing information. The FDA label for Afrezza describes the dosing structure and clinical use pattern. The prescriber should confirm that the prescribed quantity is consistent with label-directed use and explain any individualized reason for the quantity needed.

4. Include glucose logs and any hypoglycemia records. These provide objective support for the clinical argument that the limited quantity is not adequate for this patient's glycemic management.

5. Map to Humana's quantity-limit exception criteria. Request Humana's exception or medical-necessity criteria for quantity-limit overrides and address each criterion explicitly in the appeal package.

## What to Submit

• Denial notice identifying the specific quantity limit applied
• Humana's quantity-limit criteria or exception policy (request current version)
• FDA prescribing label for Afrezza (highlighting dosing guidance)
• Prescriber's individualized letter explaining the clinical basis for the prescribed quantity
• Glucose monitoring records and relevant lab results
• Chart notes supporting the dosing rationale

## Timeline

• Internal appeal: File within the period on the denial notice (often 180 days). Decision typically within 30 days; 72 hours expedited.
• External review: Request within approximately four months of final internal denial. The IRO reviews clinical evidence independently of Humana's administrative limits.